Results from ORION-3 open-label trial show twice-yearly Leqvio(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (LDL-C)
Investegate announcements from NOVARTIS AG CHF0.50(REGD), New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
AMRA Medical's MRI-based technology and informatics are featured in seven abstracts accepted for presentation at The Liver Meeting 2022 the world's "must-attend" hepatology meeting. AMRA Medical